Sofinnova closes €725 million fund to back European biotech expansion
Resumen detallado
By Bhanvi Satija LONDON, Nov 16 (Reuters) - Life sciences investment firm Sofinnova Partners said on Monday it has closed a second crossover fund at €725 million ($799 million), above its original target, to back European biotechs that are seeking to compete globally.
LONDON, Nov 16 (Reuters) - Life sciences investment firm Sofinnova Partners said on Monday it has closed a second crossover fund at €725 million ($799 million), above its original target, to back European biotechs that are seeking to compete globally.
A crossover fund typically invests in private companies approaching commercialisation or public listings, bridging the gap between venture capital and public-market investing.
The raise comes at a time when drugmakers are pushing European governments to increase spending on medicines, faster trials and other policies that would prevent the region from losing ground to the US and China.
At the same time, cash-strapped governments in Europe are under pressure to rethink how they pay for innovative medicines.
Europe has outstanding science and companies, said Kinam Hong, a partner at Sofinnova, told Reuters in an interview.
"It doesn’t have an innovation gap, but it really has a financing growth capital problem," he said.
Hong said the fund, called Crossover II, is the biggest ever for the firm and will focus on European biotechs and medtech companies looking to commercialise their medicines or devices, with some selective investments in the US and elsewhere.
Through the fund, Sofinnova expects to back about 15 companies and has already invested in rare-disease biotech Hemab Therapeutics, multiple myeloma drug developer CellCentric and Neurent Medical, a chronic rhinitis device maker.
Hong said the firm plans to be an active investor, helping companies with leadership, trials and listings. He added that the aim is to build companies for "successful longevity" even without mergers and acquisitions.
Inicio del artículo, extracto de Euronext. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (live.euronext.com)